Mumbai, Maharashtra, 19th of August, 2026 : Another major name is set to make its debut in the IPO market. Pharmaceutical company Symbiotech Pharmalab Limited is coming up with an initial public offering (IPO) worth ₹1,757 crore. The IPO will open on August 24, 2026, and close on August 27, 2026, while bidding for anchor investors will take place on August 21.
The IPO price band has been fixed at ₹938 to ₹988 per equity share. Investors can bid for a minimum of 15 shares, followed by bids in multiples of 15 shares. Each equity share has a face value of ₹2.
The issue comprises a fresh issue of shares worth up to ₹150 crore, while existing shareholders will offer shares worth up to ₹1,607 crore through an Offer for Sale (OFS).
According to the company, the net proceeds from the fresh issue will be used for the full or partial prepayment or repayment of outstanding borrowings, along with general corporate purposes.
The OFS will include Satvani Holdings LLP, Rosewood Investments, and India Business Excellence Fund-3. The company has proposed listing its shares on both the BSE and NSE.
Eligible employees participating in the employee reservation portion will also receive a ₹90 discount
With its sizeable issue size, pharma-sector focus and proposed listing on both major stock exchanges, the Symbiotech Pharmalab IPO could attract significant attention from investors across the primary market, particularly those tracking the pharmaceutical sector.
More Stories
IIM Nagpur Felicitates Padma Shri Satyanarayanji Nuwal.
Warangal Temple Priest Fulfils His 15-Year Cricket Dream, Now Creating Opportunities For Grassroots Players.
From AI To Robotics, Students Showcase Their Technology Skills.